Alzheimer's disease (AD) is a neurodegenerative disease closely related to the accumulation of beta-amyloid (Aβ) plaques. Growth differentiation factor 11 (GDF11) is one of the proteins that play a role in the aggravation of AD. Decreased concentration of GDF11 disrupts regenerative nervous system, blood vessels, and various vital systems. Low levels of GDF11 with age can be overcome with recombinant GDF11 (rGDF11) to rejuvenate the regenerative effect. Based on research results, rGDF11 enhance the proliferation rate of neuronal precursor cells as well as angiogenesis. rGDF11 can replace lost levels of GDF11, overcome astrogliosis and activation of nerve cell microglia. Therapeutic effect of rGDF11 leads to an improved prognosis in AD patients by neurogenesis and angiogenesis. The prospects of rGDF11 in the treatment of AD have great potential for further research in the future.
CITATION STYLE
de Liyis, B. G., Halim, W., & Widyadharma, I. P. E. (2022, December 1). Potential role of recombinant growth differentiation factor 11 in Alzheimer’s disease treatment. Egyptian Journal of Neurology, Psychiatry and Neurosurgery. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1186/s41983-022-00487-5
Mendeley helps you to discover research relevant for your work.